[HTML][HTML] Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX …
Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …
A randomized phase 2 study of ADXS11-001 Listeria monocytogenes–Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer
Objectives A global unmet medical need exists for effective treatments for persistent,
recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently …
recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently …
[HTML][HTML] Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected …
This multicenter phase III study evaluated the efficacy and safety of lapatinib, an epidermal
growth factor receptor/ErbB2 inhibitor, administered concomitantly with chemoradiotherapy …
growth factor receptor/ErbB2 inhibitor, administered concomitantly with chemoradiotherapy …
[HTML][HTML] A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with …
WJ Gradishar, V Kaklamani, TP Sahoo… - European Journal of …, 2013 - Elsevier
BACKGROUND: We conducted a phase 2b, randomised, double-blind, placebo-controlled
screening trial to evaluate the addition of the multikinase inhibitor sorafenib (antiproliferative …
screening trial to evaluate the addition of the multikinase inhibitor sorafenib (antiproliferative …
The ACT‐ONE trial, a multicentre, randomised, double‐blind, placebo‐controlled, dose‐finding study of the anabolic/catabolic transforming agent, MT‐102 in subjects …
AJ Stewart Coats, V Srinivasan… - Journal of Cachexia …, 2011 - Wiley Online Library
Aims Cachexia, the wasting disorder associated with a wide range of serious illnesses
including cancer, is a major cause of morbidity and mortality. There is currently no widely …
including cancer, is a major cause of morbidity and mortality. There is currently no widely …
[HTML][HTML] Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative …
MM Jain, SU Gupte, SG Patil, AB Pathak… - Breast cancer research …, 2016 - Springer
Paclitaxel is widely used in the treatment of patients with metastatic breast cancer (MBC).
Formulations of paclitaxel contain surfactants and solvents or albumin derived from human …
Formulations of paclitaxel contain surfactants and solvents or albumin derived from human …
Immune modulation by dendritic-cell-based cancer vaccines
C Kumar, S Kohli, PP Bapsy, AK Vaid, M Jain… - Journal of …, 2017 - Springer
The interplay between host immunity and tumour cells has opened the possibility of
targeting tumour cells by modulation of the human immune system. Cancer immunotherapy …
targeting tumour cells by modulation of the human immune system. Cancer immunotherapy …
Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid …
PP Bapsy, B Sharan, C Kumar, RP Das, B Rangarajan… - Cytotherapy, 2014 - Elsevier
Background aims A phase II clinical trial of an autologous dendritic cell (DC) formulation for
the management of refractory solid malignant tumors was conducted across six sites in India …
the management of refractory solid malignant tumors was conducted across six sites in India …
ADXS11-001 immunotherapy targeting HPV-E7: Final results from a phase 2 study in Indian women with recurrent cervical cancer.
5610 Background: ADXS11-001 immunotherapy is a live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete a HPV-16-E7 fusion protein targeting HPV …
monocytogenes (Lm) bioengineered to secrete a HPV-16-E7 fusion protein targeting HPV …
[HTML][HTML] Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
T Raja, R Sud, S Addla, KK Sarkar… - Indian Journal of …, 2022 - journals.lww.com
Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist
(s)(GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review …
(s)(GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review …